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Vascular access (VA) is of the utmost importance in chronic haemodialysis in achieving adequate quality of treatment as well as for morbidity, mortality and quality of life of patient. In general, it is expected that using the best VA for the individual patient associates with the best dialysis adequacy and also with lowest morbidity and mortality. Overall, the best access is considered to be the native arteriovenous (AV) fistula, followed by grafts and central venous catheters (CVCs), 1 although in the individual patient the best choice may be different. Indeed, it is increasingly difficult to create native AV fistulae in fragile, elderly patients affected by multiple comorbidities. In addition, in many hospitals, there is a lack of optimisation of the resources necessary to timely create native fistulae and AV grafts for dialysis patients. Large differences in VA use have been observed at the country and at the facility levels. AV fistula rates range from 49% in Canada to over 90% in Japan and Russia, whose dialysis populations are very different. Con versely, CVC use ranges from less than 2% in Japan to 45% in Canada. 2 Moreover, despite similar patients' characteristics at the facility level, VA type is more strongly associated with provider choice than with patient characteristics. 3 In this perspective, it is essen tial to adequately control all the necessary steps in the process of VA creation and in its followup for the pre vention, detection and treatment of complications. To facilitate decisionmaking, it is mandatory collecting and grading the evidence, and then converting it into recommendations to help the clinician make decisions in daily clinical practice. This is why clinical practice guidelines are developed but it is not always easy to transfer them into practice, especially in the complex field of VA. The limited evidence available in many aspects of dialysis access, the diversity of medical and surgical specialities involved in VA preparation and management, and the great diversity of associated procedures are all elements of complexity in achieving guidelines that can be universally adopted.
Following the first set of guidelines published in this area over 10 years ago, 4-7 new guidelines have been recently published at the national and international levels by the UK Renal Association, 8 the Spanish Multidisciplinary Group on Vascular Access (GEMAV), 9 the European Society for Vascular Surgery (ESVS) 10 and the European Renal Association-European Dialysis and Transplant Association (ERAEDTA). 11 The ESVS clinical practice guidelines are mainly directed not only at surgeons but also at other professionals who are involved in the care of patients with haemodialysis VA. Their aim is to summarize and present the available evi dence, to assist physicians in selecting the best manage ment strategies for all patients needing VA and to approach pathologies associated with VA. These guide lines review the aspects of preoperative, perioperative and postoperative care and longterm maintenance. In addition to reviewing the main aspects that the clinician needs in daily clinical practice for decisionmaking in AV fistula issues, it also reviews areas where the surgical approach, which can pose a challenge for the surgeon, stands out.
It is also important to point out the profound differ ences between the recommendations for dialysis access from the 2007 ERAEDTA guidelines 4 and the current European Renal Best Practice guidelines. 11 The first set of clinically oriented VA recommendations was drafted by expert clinicians. Now, guideline development has moved to a more rigorous methodology involving the active presence of methodologists in the guidelines development groups, with a much greater emphasis placed on evidencebased medicine, relying almost exclusively on results of randomized control trials, sys tematic reviews and metanalysis for the formulation of suggestions and recommendations.
VA guidelines represent a useful decisionmaking tool during daily clinical practice for all professionals involved in VA management. Undoubtedly, their use can improve the quality of dialysis, the decline of associated morbimortality and the quality of life of the renal patient. That is why the Vascular Access Society, which was represented by some of the clinicians involved in the ESVS and in the ERAEDTA guidelines working groups, wants not only to praise the efforts involved in updating this field but also to appreciate the help these guidelines will provide to all professionals who assume responsibility for decisionmaking in this field every day.
However, sometimes, it may not be easy for the clini cian to find the right answer to a specific question when looking at different guidelines, addressing different issues in different ways, according to the context in which the guidelines were developed. In the ESVS guideline, for example, the issue of CVCs for haemodialysis is not addressed and guidelines do not delve into the subject of ultrasonography, including surveillance, a topic of great interest to the VA community. [12] [13] [14] The upcoming revision of the Kidney Disease Outcomes Quality Initiative (KDOQI) clinical practice guideline for VA of the National Kidney Foundation (NKF) can also present some differences, as they logically arise from different settings. This set of guidelines has been recently in public review, and it proposes a more patientspecific approach with the aims of achieving more appropriate VA choices through a LifePlan strategy to VA decisionmaking and developing patientcentred, evidencebased, decision making algorithms. We share the idea that an individual ized approach to VA choice should be preferred by clinicians, considering patients' characteristics, prefer ences and values. However, when preparing and inter preting practice guidelines, a patientspecific approach might represent a challenge.
In this context, the Vascular Access Society intends to publish some 'Position Documents' to summarize both the evidence and the recommendations regarding specific issues addressed by the different new VA guide lines. Thus, the whole VA community will have the pos sibility to better integrate the new updates into their current clinical practices in the most coherent way. The Vascular Access Society will be supporting this process.
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